Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Human P2X7 receptor causes cycle arrest in RPMI-8226 myeloma cells to alter the interaction with osteoblasts and osteoclasts

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road

    Research output: Contribution to journalReviewResearchpeer-review

  3. Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo

    Research output: Contribution to journalReviewResearchpeer-review

  2. Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

    Research output: Contribution to journalReviewResearchpeer-review

  4. Inflammation induced PD-L1-specific T cells

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

While cancer immune therapy has revolutionized the treatment of metastatic disease across a wide range of cancer diagnoses, a major limiting factor remains with regard to relying on adequate homing of anti-tumor effector cells to the tumor site both prior to and after therapy. Adoptive cell transfer (ACT) of autologous T cells have improved the outlook of patients with metastatic melanoma. Prior to the approval of checkpoint inhibitors, this strategy was the most promising. However, while response rates of up to 50% have been reported, this strategy is still rather crude. Thus, improvements are needed and within reach. A hallmark of the developing tumor is the evasion of immune destruction. Achieved through the recruitment of immune suppressive cell subsets, upregulation of inhibitory receptors and the development of physical and chemical barriers (such as poor vascularization and hypoxia) leaves the microenvironment a hostile destination for anti-tumor T cells. In this paper, we review the emerging strategies of improving the homing of effector T cells (TILs, CARs, TCR engineered T cells, etc.) through genetic engineering with chemokine receptors matching the chemokines of the tumor microenvironment. While this strategy has proven successful in several preclinical models of cancer and the strategy has moved into the first phase I/II clinical trial in humans, most of these studies show a modest (doubling) increase in tumor infiltration of effector cells, which raises the question of whether road blocks must be tackled for efficient homing. We propose a role for physical exercise in modulating the tumor microenvironment and preparing the platform for infiltration of anti-tumor immune cells. In a time of personalized medicine and genetic engineering, this "old tool" may be a way to augment efficacy and the depth of response to immune therapy.

Original languageEnglish
JournalCells
Volume7
Issue number8
ISSN2073-4409
DOIs
Publication statusPublished - 17 Aug 2018

ID: 56272613